United States: FDA Releases Draft Guidance On Postmarket Management Of Cybersecurity In Medical Devices

On January 15, 2016,  the U.S. Food and Drug Administration (FDA) published a draft guidance entitled Postmarket Management of Cybersecurity in Medical Devices (Draft Guidance), which outlines FDA's recommendations for managing postmarket cybersecurity vulnerabilities in medical devices that contain software or programmable logic and software that is a medical device, including networked medical devices. The Draft Guidance represents FDA's latest attempt to outline principles intended to enhance medical device cybersecurity throughout the product lifecycle.

Unlike other federal regulators, FDA primarily focuses on the cybersecurity risks to patient safety rather than on risks to personal information privacy and consumer protection. But, the Draft Guidance provides cybersecurity risk management recommendations that are generally consistent with those of other regulators and information security experts. For example, the FDA encourages manufacturers to follow the voluntary Framework for Improving Critical Infrastructure Cybersecurity developed by the National Institute of Standards and Technology with input from various government agencies and the private sector.

The Draft Guidance also comes shortly after the 2016 Work Plan release by the U.S. Department of Health and Human Services Office of Inspector General (OIG), which indicates that the OIG will examine whether FDA's oversight of hospitals' networked medical devices is sufficient to effectively protect associated electronic protected health information and ensure Medicare beneficiary safety. According to the OIG, its review will focus on dialysis machines, radiology systems, medication dispensing systems and other computerized medical devices that are integrated with electronic medical records and the larger health network. The cybersecurity efforts of multiple federal agencies sends a clear message that cybersecurity in health care will continue to be a priority for regulators in 2016.

The FDA requests that stakeholders submit comments on the Draft Guidance by April 21, 2016.

The following sections discuss the Draft Guidance's relationship to prior FDA cybersecurity guidance, its key recommendations and the implications for manufacturers as well as health information technology (IT) developers, health care providers and other stakeholders with responsibilities for medical device cybersecurity.

FDA's Premarket Cybersecurity Guidance

The Draft Guidance follows the FDA's release on October 2, 2014, of its final Guidance for Premarket Submissions for Management of Cybersecurity in Medical Devices, which offered recommendations to help manufacturers identify and consider issues relevant to cybersecurity risk management during the device design and development phase, as well as to prepare premarket submissions for such products. The Draft Guidance notes that manufacturers cannot mitigate cybersecurity risks through premarket controls alone. FDA emphasizes that manufacturers should monitor, identify and address cybersecurity vulnerabilities and successful exploits of vulnerabilities as part of their postmarket management of medical devices.

FDA Recommendations in Draft Guidance

Comprehensive Cybersecurity Risk Management Programs

Because cybersecurity risks to medical devices are continually evolving, the FDA believes it is "essential" that manufacturers implement ongoing comprehensive cybersecurity risk management programs as part of their compliance with the FDA's Quality Systems Regulation (QSR). The QSR sets forth requirements for the methods used in, and the facilities and controls used for, the design, manufacture, packaging, labeling, storage, installation and servicing of all finished medical devices intended for human use, including requirements for complaint handling, quality audits, corrective and preventive actions, software validation and risk analysis, and servicing. The QSR is intended to ensure that finished devices will be safe and effective and otherwise in compliance with the Federal Food, Drug, and Cosmetic Act (FDCA).

In general, cybersecurity risk management programs should address vulnerabilities that may impact patient safety and permit unauthorized access, modification, misuse, denial of use or unauthorized use of information. Critical components of such programs include:

  • Defining Essential Clinical Performance. Defining "essential clinical performance" (i.e., the performance that is necessary to achieve freedom from unacceptable clinical risk) in order to develop mitigations that protect, respond and recover from the cybersecurity risk
  • Identification. Monitoring cybersecurity information sources to identify and detect cybersecurity vulnerabilities and risk
  • Intake and Handling Processes. Establishing and communicating processes for vulnerability intake and handling
  • Risk Assessment. Characterizing and assessing the exploitability and severity of detected vulnerabilities and risks
  • Disclosure Policy. Adopting a coordinated vulnerability disclosure policy and practice
  • Mitigation and Response. Responding to risks and vulnerabilities by deploying mitigations that address cybersecurity risk early and prior to exploitation

Defining Essential Clinical Performance

The Draft Guidance advises device manufacturers to define a device's essential clinical performance; to identify the severity of different outcomes if the device is compromised; and to set forth risk acceptance criteria. According to the FDA, defining essential clinical performance will enable a device manufacturer to assess the impact of security vulnerabilities and triage such vulnerabilities for remediation.

Cybersecurity Information Sharing

As part of the identification component of a comprehensive cybersecurity risk management program, FDA encourages device manufacturers to participate in a cybersecurity Information Sharing Analysis Organization (ISAO) to facilitate sharing and dissemination of cybersecurity information and intelligence pertaining to vulnerabilities and threats across multiple sectors. Throughout the Draft Guidance, FDA emphasizes that cybersecurity is a shared responsibility with health care providers and other stakeholders.

Risk Assessment Process

FDA recommends that device manufacturers establish a defined, objective process to systematically evaluate risk and determine whether a cybersecurity vulnerability affecting a medical device presents an acceptable or unacceptable risk. FDA emphasizes that an analysis of the risks to a device's essential clinical performance should include an assessment of both the exploitability of the cybersecurity vulnerability and the severity of health impact to patients if the vulnerability were exploited. To perform these assessments, the FDA recommends using a cybersecurity vulnerability assessment tool to rate vulnerabilities and determine the need for and urgency of the response (e.g., the Common Vulnerability Scoring System) and the ANSI/AAMI/ISO 14971 standard (Application of Risk Management to Medical Devices) to assess the severity impact to health, if the cybersecurity vulnerability were to be exploited.

In all cases, FDA recommends that manufacturers make a binary determination that a vulnerability is either controlled or uncontrolled using an established process that is tailored to the product, its essential clinical performance, and the situation. A vulnerability is considered controlled when there is a sufficiently low residual risk that the device's essential clinical performance could be compromised by successful exploitation of the vulnerability. In contrast, a vulnerability is uncontrolled when there is unacceptable residual risk that the device's essential clinical performance could be compromised due to insufficient risk mitigation and compensating controls with respect to such vulnerability.

Risk mitigations, including compensating controls, should be implemented when necessary to bring the residual risk to an acceptable level.

Response to Controlled Risks/Vulnerabilities and Device Manufacturer Reporting Requirements

When a manufacturer determines that a vulnerability is controlled, the FDA recommends that it adopt the following changes or compensating controls:

  • Routine updates and patches intended to increase device security and/or remediate vulnerabilities (but not to reduce a risk to health or correct a violation of the FDCA) and other changes to a device made solely to strengthen cybersecurity (which are typically considered "device enhancements" and generally do not trigger FDA reporting requirements under FDA's correction and removal reporting requirements); and
  • For premarket approval devices with periodic reporting requirements, manufacturers should report newly acquired information concerning cybersecurity vulnerabilities and device changes made as part of cybersecurity routine updates and patches to FDA in a periodic (annual) report.

Response to Uncontrolled Risks/Vulnerabilities

For vulnerabilities determined to be uncontrolled risks, the FDA recommends the following changes or compensating control actions:

  • Manufacturers should remediate the vulnerabilities to reduce the risk of compromise to essential clinical performance to an acceptable level;
  • If it is not feasible or immediately practicable to implement a complete solution to remove a cybersecurity vulnerability from a medical device, manufacturers should identify and implement risk mitigations and compensating controls, such as a work-arounds or temporary fixes, to adequately mitigate the risk;
  • Manufacturers should report these vulnerabilities to the FDA under the correction and removal reporting requirements, unless reported under another FDA reporting requirement. The FDA states, however, that it does not intend to enforce reporting requirements under the correction and removal requirement if: 
    - There are no known serious adverse events or deaths associated with the vulnerability;
    - Within 30 days of learning of the vulnerability, the manufacturer identifies and implements device changes and/or compensating controls to bring the residual risk to an acceptable level and notifies users; and
    - The manufacturer is a participating member of an ISAO.
  • Remediation of devices with annual reporting requirements (e.g., Class III devices) should be included in the annual report;
  • Manufacturers should evaluate the device changes to assess the need to submit a premarket submission;
  • Manufacturers should provide their customer base and user community (e.g., hospitals, physicians, patients)  with relevant information on recommended work-arounds, temporary fixes and residual cybersecurity risks so that they can take appropriate steps to mitigate the risk and make informed decisions; and
  • For premarket approval devices with periodic reporting requirements, information concerning cybersecurity vulnerabilities and the device changes and compensating controls implemented in response to this information should be reported to FDA in a periodic annual report.

If a device manufacturer does not take steps to remediate an uncontrolled risk that is essential to its clinical performance, the FDA may find a reasonable probability that use of, or exposure to, the device will cause serious adverse health consequences or death. The FDA will consider such devices to be in violation of the FDCA and subject to enforcement action.

Submitting Comments

Stakeholders that wish to submit comments to FDA should contact their regular McDermott lawyer or the authors of this newsletter. To ensure consideration of comments before the FDA begins working on the final version of the guidance, FDA recommends that stakeholders submit comments by April 21, 2016.

FDA Releases Draft Guidance On Postmarket Management Of Cybersecurity In Medical Devices

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.